FDA Approves Novo Nordisk A/S (NVO) Recombinant Therapy to Treat Rare Bleeding Disorder
More News related to NVO
- Goldman Sachs Upgrades Novo Nordisk A/S (NVO) to Buy
- Novo Nordisk A/S -- Treasury Stock
- Medarex (MEDX) Will Receive Milestone Payment from Novartis (NVO) for FDA Approval of Ilaris
- Novo Nordisk Insulin Analogs Have Proven Safety Profiles
- Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
Novo Nordisk A/S (NYSE: NVO) said the FDA has approved a new indication for NovoSeven Coagulation Factor VIIa (Recombinant), making it the first and only recombinant therapy approved for the treatment of acquired hemophilia, a rare and potentially fatal bleeding disorder. As a recombinant therapy, NovoSeven is not plasma-derived and poses no risk of human viral transmission through its use.
The FDA approved NovoSeven for treatment of bleeding episodes in patients with acquired hemophilia, and in the prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia.
Related Categories
FDAStocks Mentioned
-29.88Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
